Table 1 Demographics and disease-characteristics of the 1137 RA patients treated with bDMARDs
Demographics and disease-characteristics | |
|---|---|
Women | 880 (77.4) |
Age, years | 58.9 ± 12.3 |
Disease duration, years | 16.2 ± 11.0 |
RF positive (n = 1132) | 981 (86.7) |
ACPA positive (n = 360) | 297 (82.5) |
Erosive disease (n = 1130) | 980 (86.7) |
DAS28, before start on present bDMARDs (n = 808) | 5.16 ± 1.23 |
DAS28, last follow-up on present bDMARDs (n = 814) | 3.02 ± 1.26 |
HAQ score, before start on present bDMARDs (n = 854) | 1.29 ± 0.64 |
HAQ score, last follow-up on present bDMARDs (n = 839) | 0.93 ± 0.65 |
Present bDMARDs | |
TNF-inhibitor (infliximab, etanercept, adalimumab, certolizumab, golimumab) | 881 (77.5) |
Rituximab | 183 (16.1) |
Tocilizumab | 56 (4.9) |
Abatacept | 13 (1.1) |
Anakinra | 4 (0.4) |
Concomitant csDMARDs and glucocorticosteroids at last follow-up (n = 983) | |
Any csDMARDs | 826 (84.0) |
Methotrexate | 749 (76.2) |
Glucocorticosteroids (prednisolone) | 284 (28.9) |
Numerical number of bDMARDs | |
1 | 683 (60.1) |
2 | 319 (28.1) |
3 | 97 (8.5) |
≥4 | 38 (3.3) |